{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:15:31Z","timestamp":1790464531799,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                <jats:title>Abstract<\/jats:title>\n                <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is the most prevalent neurological complication of cancer treatment which involves sensory and motor nerve dysfunction. Severe CIPN has been reported in around 5% of patients treated with single and up to 38% of patients treated with multiple chemotherapeutic agents. Present medications available for CIPN are the use of opioids, nonsteroidal anti-inflammatory agents, and tricyclic antidepressants, which are only marginally effective in treating neuropathic symptoms. In reality, symptom reappears after these drugs are discontinued. The pathogenesis of CIPN has not been sufficiently recognized and methods for the prevention and treatment of CIPN remain vulnerable to therapeutic problems. It has witnessed that the present medicines available for the disease offer only symptomatic relief for the short term and have severe adverse side effects. There is no standard treatment protocol for preventing, reducing, and treating CIPN. Therefore, there is a need to develop curative therapy that can be used to treat this complication. Melittin is the main pharmacological active constituent of honeybee venom and has therapeutic values including in chemotherapeutic-induced peripheral neuropathy. It has been shown that melittin and whole honey bee venom are effective in treating paclitaxel and oxaliplatin-induced peripheral neuropathy. The use of melittin against peripheral neuropathy caused by chemotherapy has been limited despite having strong therapeutic efficacy against the disease. Melittin mediated haemolysis is the key reason to restrict its use. In our study, it is found that \u03b1-Crystallin (an eye lens protein) is capable of inhibiting melittin-induced haemolysis which gives hope of using an appropriate combination of melittin and \u03b1-Crystallin in the treatment of CIPN. The review summarizes the efforts made by different research groups to address the concern with melittin in the treatment of chemotherapeutic-induced neuropathy. It also focuses on the possible approaches to overcome melittin-induced haemolysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphic Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s12032-021-01496-9","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T02:02:51Z","timestamp":1617328971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Melittin, a honeybee venom derived peptide for the treatment of chemotherapy-induced peripheral neuropathy"],"prefix":"10.1007","volume":"38","author":[{"given":"Tenzin","family":"Tender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh Ravishankar","family":"Rahangdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridevi","family":"Balireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavan","family":"Nampoothiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Krishna","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6538-7758","authenticated-orcid":false,"given":"Hariharapura","family":"Raghu Chandrashekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"issue":"3","key":"1496_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10549-017-4635-4","volume":"168","author":"AJ Alhuqail","year":"2018","unstructured":"Alhuqail AJ, Alzahrani A, Almubarak H, Al-Qadheeb S, Alghofaili L, Almoghrabi N, Alhussaini H, Park BH, Colak D, Karakas B. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients. Breast Cancer Res Treat. 2018;168(3):695\u2013702.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"1496_CR2","doi-asserted-by":"publisher","first-page":"888","DOI":"10.4161\/cbt.25945","volume":"14","author":"B Karakas","year":"2013","unstructured":"Karakas B, Colak D, Kaya N, Ghebeh H, Al-Qasem A, Hendrayani F, Toulimat M, Al-Tweigeri T, Park BH, Aboussekhra A. Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients. Cancer Biol Ther. 2013;14(10):888\u201396.","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"1496_CR3","first-page":"712","volume":"58","author":"M Ghafoor","year":"2003","unstructured":"Ghafoor M, Schuyten R, Bener A. Epidemiology of prostate cancer in United Arab Emirates. Med J Malays. 2003;58(5):712\u20136.","journal-title":"Med J Malays"},{"issue":"6","key":"1496_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.clgc.2015.05.010","volume":"13","author":"L Hilal","year":"2015","unstructured":"Hilal L, Shahait M, Mukherji D, Charafeddine M, Farhat Z, Temraz S, Khauli R, Shamseddine A. Prostate cancer in the Arab world: a view from the inside. Clin Genitourin Cancer. 2015;13(6):505\u201311.","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"1496_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11910-017-0757-7","volume":"17","author":"C Cioroiu","year":"2017","unstructured":"Cioroiu C, Weimer LH. Update on chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci Rep. 2017;17(6):47.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"1496_CR6","doi-asserted-by":"publisher","first-page":"e00558","DOI":"10.1002\/brb3.558","volume":"7","author":"M Banach","year":"2017","unstructured":"Banach M, Juranek JK, Zygulska AL. Chemotherapy-induced neuropathies\u2014a growing problem for patients and health care providers. Brain Behav. 2017;7(1):e00558.","journal-title":"Brain Behav"},{"issue":"1","key":"1496_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/bja\/aet208","volume":"111","author":"MT Fallon","year":"2013","unstructured":"Fallon MT. Neuropathic pain in cancer. Br J Anaesth. 2013;111(1):105\u201311.","journal-title":"Br J Anaesth"},{"issue":"12","key":"1496_CR8","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","volume":"155","author":"M Seretny","year":"2014","unstructured":"Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain\u00ae. 2014;155(12):2461\u201370.","journal-title":"Pain\u00ae"},{"issue":"6","key":"1496_CR9","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ana.24951","volume":"81","author":"NP Staff","year":"2017","unstructured":"Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772\u201381.","journal-title":"Ann Neurol"},{"issue":"1","key":"1496_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11764-014-0379-x","volume":"9","author":"D Jones","year":"2015","unstructured":"Jones D, Zhao F, Brell J, Lewis MA, Loprinzi CL, Weiss M, Fisch MJ. Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer. J Cancer Surviv. 2015;9(1):1.","journal-title":"J Cancer Surviv"},{"issue":"23","key":"1496_CR11","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1200\/JCO.2016.71.3552","volume":"35","author":"KM Winters-Stone","year":"2017","unstructured":"Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, Faithfull S. Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2017;35(23):2604.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1496_CR12","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EM Smith","year":"2013","unstructured":"Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359\u201367.","journal-title":"JAMA"},{"key":"1496_CR13","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","volume":"32","author":"DL Hershman","year":"2014","unstructured":"Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014;32(18):1941\u20131967.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1496_CR14","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.ejca.2008.04.018","volume":"44","author":"S Wolf","year":"2008","unstructured":"Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44(11):1507\u201315.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1496_CR15","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/0014-4886(74)90197-6","volume":"43","author":"PD Wall","year":"1974","unstructured":"Wall PD, Gutnick M. Ongoing activity in peripheral nerves: the physiology and pharmacology of impulses originating from a neuroma. Exp Neurol. 1974;43(3):580\u201393.","journal-title":"Exp Neurol"},{"issue":"8","key":"1496_CR16","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1054\/bjoc.2001.2024","volume":"85","author":"MJ McKeage","year":"2001","unstructured":"McKeage MJ, Hsu T, Screnci D, Haddad G, Baguley BC. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer. 2001;85(8):1219\u201325.","journal-title":"Br J Cancer"},{"issue":"6","key":"1496_CR17","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/ijms20061451","volume":"20","author":"R Zaj\u0105czkowska","year":"2019","unstructured":"Zaj\u0105czkowska R, Kocot-K\u0119pska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451.","journal-title":"Int J Mol Sci"},{"key":"1496_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.expneurol.2016.11.015","volume":"288","author":"EL Gornstein","year":"2017","unstructured":"Gornstein EL, Schwarz TL. Neurotoxic mechanisms of paclitaxel are local to the distal axon and independent of transport defects. Exp Neurol. 2017;288:153\u201366.","journal-title":"Exp Neurol"},{"issue":"5","key":"1496_CR19","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00280-015-2863-z","volume":"76","author":"M Lopus","year":"2015","unstructured":"Lopus M, Smiyun G, Miller H, Oroudjev E, Wilson L, Jordan MA. Mechanism of action of ixabepilone and its interactions with the \u03b2III-tubulin isotype. Cancer Chemother Pharmacol. 2015;76(5):1013\u201324.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1496_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0753-3322(02)00168-3","volume":"56","author":"P Richardson","year":"2002","unstructured":"Richardson P, Hideshima T, Anderson K. Thalidomide in multiple myeloma. Biomed Pharmacother. 2002;56(3):115\u201328.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"1496_CR21","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1523\/JNEUROSCI.3127-04.2005","volume":"25","author":"P Fernyhough","year":"2005","unstructured":"Fernyhough P, Smith DR, Schapansky J, Van Der Ploeg R, Gardiner NJ, Tweed CW, Kontos A, Freeman L, Purves-Tyson TD, Glazner GW. Activation of nuclear factor-\u03baB via endogenous tumor necrosis factor \u03b1 regulates survival of axotomized adult sensory neurons. J Neurosci. 2005;25(7):1682\u201390.","journal-title":"J Neurosci"},{"issue":"2","key":"1496_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3324\/haematol.2009.012674","volume":"95","author":"B Mohty","year":"2010","unstructured":"Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010;95(2):311\u20139.","journal-title":"Haematologica"},{"issue":"8","key":"1496_CR23","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1021\/acs.chemrestox.7b00127","volume":"30","author":"TH Wani","year":"2017","unstructured":"Wani TH, Chakrabarty A, Shibata N, Yamazaki H, Guengerich FP, Chowdhury G. The dihydroxy metabolite of the teratogen thalidomide causes oxidative DNA damage. Chem Res Toxicol. 2017;30(8):1622\u20138.","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"1496_CR24","first-page":"38","volume":"15","author":"MR Jones","year":"2020","unstructured":"Jones MR, Urits I, Wolf J, Corrigan D, Colburn L, Peterson E, Williamson A, Viswanath O. Drug-induced peripheral neuropathy: a narrative review. Curr Clin Pharmacol. 2020;15(1):38\u201348.","journal-title":"Curr Clin Pharmacol"},{"issue":"11","key":"1496_CR25","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1002\/cncr.31248","volume":"124","author":"J Ma","year":"2018","unstructured":"Ma J, Kavelaars A, Dougherty PM, Heijnen CJ. Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: targeting the source. Cancer. 2018;124(11):2289\u201398.","journal-title":"Cancer"},{"issue":"6","key":"1496_CR26","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00520-010-0911-0","volume":"19","author":"DL Barton","year":"2011","unstructured":"Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD, Kugler JW, Hoff KL, Reddy PS, Rowland KM. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011;19(6):833\u201341.","journal-title":"Support Care Cancer"},{"key":"1496_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.neuroscience.2011.12.023","volume":"203","author":"WH Xiao","year":"2012","unstructured":"Xiao WH, Zheng H, Bennett GJ. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience. 2012;203:194\u2013206.","journal-title":"Neuroscience"},{"issue":"2","key":"1496_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3831\/KPI.2006.9.2.079","volume":"9","author":"SH Choi","year":"2006","unstructured":"Choi SH, Cha BC, Kwon KR. Component analysis of sweet BV and clinical trial on antibody titer and allergic reactions. J Pharmacopuncture. 2006;9(2):79\u201386.","journal-title":"J Pharmacopunct"},{"issue":"2","key":"1496_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.neures.2006.03.003","volume":"55","author":"YB Kwon","year":"2006","unstructured":"Kwon YB, Yoon SY, Kim HW, Roh DH, Kang SY, Ryu YH, Choi SM, Han HJ, Lee HJ, Kim KW, Beitz AJ. Substantial role of locus coeruleus-noradrenergic activation and capsaicin-insensitive primary afferent fibers in bee venom\u2019s anti-inflammatory effect. Neurosci Res. 2006;55(2):197\u2013203.","journal-title":"Neurosci Res"},{"issue":"3","key":"1496_CR30","first-page":"61","volume":"9","author":"JS Lee","year":"2006","unstructured":"Lee JS, Lee JY, Kwon KR, Lee HC. A study on allergic responses between bee venom and sweet bee venom pharmacopuncture. J Korean Inst Herb Acupunct. 2006;9(3):61\u201377.","journal-title":"J Korean Inst Herb Acupunct"},{"issue":"2","key":"1496_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0304-3940(01)01989-9","volume":"308","author":"YB Kwon","year":"2001","unstructured":"Kwon YB, Kang MS, Han HJ, Beitz AJ, Lee JH. Visceral antinociception produced by bee venom stimulation of the Zhongwan acupuncture point in mice: role of \u03b12 adrenoceptors. Neurosci Lett. 2001;308(2):133\u20137.","journal-title":"Neurosci Lett"},{"issue":"3","key":"1496_CR32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1292\/jvms.65.349","volume":"65","author":"HW Kim","year":"2003","unstructured":"Kim HW, Kwon YB, Ham TW, Roh DH, Yoon SY, Lee HJ, Han HJ, Yang IS, Beitz AJ, Lee JH. Acupoint stimulation using bee venom attenuates formalin-induced pain behavior and spinal cord fos expression in rats. J Vet Med Sci. 2003;65(3):349\u201355.","journal-title":"J Vet Med Sci"},{"issue":"1","key":"1496_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jphs.2019.03.009","volume":"140","author":"JE Lee","year":"2019","unstructured":"Lee JE, Shah VK, Lee EJ, Oh MS, Choi JJ. Melittin\u2014a bee venom component\u2014enhances muscle regeneration factors expression in a mouse model of skeletal muscle contusion. J Pharmacol Sci. 2019;140(1):26\u201332.","journal-title":"J Pharmacol Sci"},{"issue":"6","key":"1496_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jpain.2004.05.003","volume":"5","author":"DH Roh","year":"2004","unstructured":"Roh DH, Kwon YB, Kim HW, Ham TW, Yoon SY, Kang SY, Han HJ, Lee HJ, Beitz AJ, Lee JH. Acupoint stimulation with diluted bee venom (apipuncture) alleviates thermal hyperalgesia in a rodent neuropathic pain model: involvement of spinal alpha2-adrenoceptors. J Pain. 2004;5(6):297\u2013303.","journal-title":"J Pain"},{"issue":"1","key":"1496_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1742-2094-8-69","volume":"8","author":"EJ Yang","year":"2011","unstructured":"Yang EJ, Kim SH, Yang SC, Lee SM, Choi SM. Melittin restores proteasome function in an animal model of ALS. J Neuroinflammation. 2011;8(1):69.","journal-title":"J Neuroinflamm"},{"issue":"2","key":"1496_CR36","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1177\/1534735411413265","volume":"11","author":"JW Park","year":"2012","unstructured":"Park JW, Jeon JH, Yoon J, Jung TY, Kwon KR, Cho CK, Lee YW, Sagar S, Wong R, Yoo HS. Effects of sweet bee venom pharmacopuncture treatment for chemotherapy-induced peripheral neuropathy: a case series. Integr Cancer Ther. 2012;11(2):166\u201371.","journal-title":"Integr Cancer Ther"},{"issue":"11","key":"1496_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/toxins9110351","volume":"9","author":"J Choi","year":"2017","unstructured":"Choi J, Jeon C, Lee JH, Jang JU, Quan FS, Lee K, Kim W, Kim SK. Suppressive effects of bee venom acupuncture on paclitaxel-induced neuropathic pain in rats: mediation by spinal \u03b12-adrenergic receptor. Toxins. 2017;9(11):351.","journal-title":"Toxins"},{"issue":"3","key":"1496_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jpain.2008.09.002","volume":"10","author":"SY Yoon","year":"2009","unstructured":"Yoon SY, Roh DH, Kwon YB, Kim HW, Seo HS, Han HJ, Lee HJ, Beitz AJ, Lee JH. Acupoint stimulation with diluted bee venom (apipuncture) potentiates the analgesic effect of intrathecal clonidine in the rodent formalin test and in a neuropathic pain model. J Pain. 2009;10(3):253\u201363.","journal-title":"J Pain"},{"key":"1496_CR39","doi-asserted-by":"crossref","unstructured":"Jones SL. Editors: Stephen Waman, Donald G. Stein, Dick Swaab, Howard Field. Descending noradrenergic influences on pain. In: Progress in brain research\u00a0 (Vol. 88, p. 381\u2013394). 1991. Elsevier.","DOI":"10.1016\/S0079-6123(08)63824-8"},{"issue":"7","key":"1496_CR40","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/toxins11070396","volume":"11","author":"S Choi","year":"2019","unstructured":"Choi S, Chae HK, Heo H, Hahm DH, Kim W, Kim SK. Analgesic effect of melittin on oxaliplatin-induced peripheral neuropathy in rats. Toxins. 2019;11(7):396.","journal-title":"Toxins"},{"issue":"1","key":"1496_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbapap.2005.07.017","volume":"1752","author":"N Peiren","year":"2005","unstructured":"Peiren N, Vanrobaeys F, de Graaf DC, Devreese B, Van Beeumen J, Jacobs FJ. The protein composition of honeybee venom reconsidered by a proteomic approach. Biochimica et Biophysica Acta (BBA) Proteins Proteomics. 2005;1752(1):1\u20135.","journal-title":"Biochimica et Biophysica Acta (BBA) Proteins Proteomics"},{"issue":"3","key":"1496_CR42","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/wnan.126","volume":"3","author":"H Pan","year":"2011","unstructured":"Pan H, Soman NR, Schlesinger PH, Lanza GM, Wickline SA. Cytolytic peptide nanoparticles (\u2018NanoBees\u2019) for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3(3):318\u201327.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"9","key":"1496_CR43","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1172\/JCI38842","volume":"119","author":"NR Soman","year":"2009","unstructured":"Soman NR, Baldwin SL, Hu G, Marsh JN, Lanza GM, Heuser JE, Arbeit JM, Wickline SA, Schlesinger PH. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Investig. 2009;119(9):2830\u201342.","journal-title":"J Clin Investig"},{"issue":"1","key":"1496_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1039\/C4TB01401D","volume":"3","author":"B Cheng","year":"2015","unstructured":"Cheng B, Thapa B, Remant KC, Xu P. Dual secured nano-melittin for the safe and effective eradication of cancer cells. J Mater Chem B. 2015;3(1):25\u20139.","journal-title":"J Mater Chem B"},{"issue":"2","key":"1496_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/toxins8020033","volume":"8","author":"W Kim","year":"2016","unstructured":"Kim W, Kim MJ, Go D, Min BI, Na HS, Kim SK. Combined effects of bee venom acupuncture and morphine on oxaliplatin-induced neuropathic pain in mice. Toxins. 2016;8(2):33.","journal-title":"Toxins"},{"issue":"21","key":"1496_CR46","doi-asserted-by":"publisher","first-page":"10449","DOI":"10.1073\/pnas.89.21.10449","volume":"89","author":"J Horwitz","year":"1992","unstructured":"Horwitz J. Alpha-crystallin can function as a molecular chaperone. Proc Natl Acad Sci. 1992;89(21):10449\u201353.","journal-title":"Proc Natl Acad Sci"},{"key":"1496_CR47","doi-asserted-by":"crossref","unstructured":"Jester JV. Editor: John Davey. Corneal crystallins and the development of cellular transparency. In: Seminars in cell & developmental biology (Vol. 19, No. 2, p. 82\u201393). 2008. Academic Press.","DOI":"10.1016\/j.semcdb.2007.09.015"},{"issue":"9","key":"1496_CR48","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1073\/pnas.88.9.3652","volume":"88","author":"R Klemenz","year":"1991","unstructured":"Klemenz R, Fr\u00f6hli E, Steiger RH, Sch\u00e4fer R, Aoyama AK. Alpha B-crystallin is a small heat shock protein. Proc Natl Acad Sci. 1991;88(9):3652\u20136.","journal-title":"Proc Natl Acad Sci"},{"key":"1496_CR49","doi-asserted-by":"crossref","unstructured":"Bhat SP. Editors: Frank Petersen, Rene Amstutz. Crystallins, genes and cataract. In: Progress in drug research (p. 205\u2013262). 2003. Birkh\u00e4user, Basel.","DOI":"10.1007\/978-3-0348-8012-1_7"},{"issue":"3","key":"1496_CR50","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/0014-4835(85)90152-6","volume":"40","author":"JA Thomson","year":"1985","unstructured":"Thomson JA, Augusteyn RC. Ontogeny of human lens crystallins. Exp Eye Res. 1985;40(3):393\u2013410.","journal-title":"Exp Eye Res"},{"issue":"6","key":"1496_CR51","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1444-0938.2004.tb03095.x","volume":"87","author":"RC Augusteyn","year":"2004","unstructured":"Augusteyn RC. \u03b1-crystallin: a review of its structure and function. Clin Exp Optom. 2004;87(6):356\u201366.","journal-title":"Clin Exp Optom"},{"issue":"6","key":"1496_CR52","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1074\/jbc.275.6.3767","volume":"275","author":"KK Sharma","year":"2000","unstructured":"Sharma KK, Kumar RS, Kumar GS, Quinn PT. Synthesis and characterization of a peptide identified as a functional element in \u03b1A-crystallin. J Biol Chem. 2000;275(6):3767\u201371.","journal-title":"J Biol Chem"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01496-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-021-01496-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01496-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T05:50:32Z","timestamp":1675144232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-021-01496-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1496"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01496-9","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,2]]},"assertion":[{"value":"29 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"52"}}